Nonsense mutation Duchenne muscular dystrophy (nmDMD) patients living in the European Union may soon experience relief from their condition due to the European Commission granting PTC Therapeutics, Inc. conditional marketing for Translarna™ (ataluren). PTC Therapeutics may now market Translarna in the 28 Member States of…
News
Recent Posts
- Building small habits through exercise to stay strong with ALS
- Molecular changes appear before ALS symptoms in SOD1 mouse model
- Coya 302: A New Approach to Neurodegeneration
- Guest Voice: Love protects our marriage in the ‘Suffering Wars’ of ALS
- Researchers identify 10 genes that may help diagnose, track ALS